KLRS on Nasdaq

Kalaris Therapeutics, Inc.

American biological products company, incorporated in Delaware.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Zivo Bioscience, Inc., Abpro Holdings, Inc. or Titan Pharmaceuticals, or pick any stock.

TickerKLRS on Nasdaq
IndustryBiological Products, (No Diagnostic Substances)
HeadquartersDE
Incorporated inDE²
Business address400 Connell Drive, Suite 5500, Berkeley Heights, Nj 07922²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

-16182.4%Operating margin³

-14447.9%Net margin³

-$20.5MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2019

Research and development

Research and development100¢$16.2M

Out of $165.0K in revenue.³ The company lost money this year.

Financial statements

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁶

Period ending	2025-12-31	2024-12-31
General and administrative (including $322 and $230 for a related party)	$15.4M	$6.7M
Total operating expenses	$46.2M	$51.7M
Loss from operations	-$46.2M	-$51.7M
Change in fair value of derivative liabilities (including $1,165 and $2,039 for a related party)	$1.2M	$2.1M
Interest expense (including $1,384 and $2,656 for a related party)	-$1.4M	-$2.7M
Loss on extinguishment and on issuance of convertible promissory notes (including $169 and $34,692 for a related party)	-$186.0K	-$38.0M
Other income, net	$2.7M	$188.0K
Total other income (expense), net	$2.7M	-$17.4M
Net loss	-$43.4M	-$69.2M
Net loss per share attributable to common stockholders - basic	-$2.85	-$51.77
Net loss per share attributable to common stockholders - diluted	-$2.85	-$51.77
Weighted-average shares outstanding - basic	15.3M shares	1.3M shares
Weighted-average shares outstanding - diluted	15.3M shares	1.3M shares
Unrealized gain on marketable securities, net of tax	$6.0K	$0
Total other comprehensive income	$6.0K	$0
Comprehensive loss	-$43.4M	-$69.2M
Research and development expenses	$30.8M	$45.0M
Change in fair value of tranche liability	$365.0K	$21.0M
Interest expense	$1.4M	$2.7M

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁶

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$98.1M	$1.6M
Short-term marketable securities	$19.9M	$0
Prepaid expenses and other current assets	$827.0K	$967.0K
Total current assets	$118.8M	$2.6M
Deferred transaction costs	$0	$3.1M
Operating lease right-of-use assets	$1.5M	$0
Restricted cash	$499.0K	$0
Other non-current assets	$953.0K	$410.0K
Total assets	$121.7M	$6.2M
Accounts payable	$1.3M	$1.6M
Convertible promissory notes, net of discount of $1,298 (including $0 and $18,670 due to a related party)	$0	$19.5M
Derivative liabilities (including $0 and $995 due to a related party)	$0	$1.0M
Operating lease liabilities, current	$316.0K	$0
Total current liabilities	$9.7M	$24.7M
Royalty obligation - related party	$32.1M	$32.1M
Operating lease liabilities, long-term	$1.1M	$0
Total liabilities	$42.9M	$56.8M
Redeemable convertible preferred stock, $0.00001 par value, no shares authorized, issued and outstanding as of December 31, 2025; 75,151,340 shares authorized as of December 31, 2024; 43,151,340 shares issued and outstanding as of December 31, 2024; liquidation preference of $0 as of December 31, 2025	$0	$46.0M
Common stock, $0.0001 and $0.00001 par value as of December 31, 2025 and 2024, respectively; 300,000,000 and 86,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 22,902,418 and 1,356,431 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$2.0K	$0
Additional paid-in capital	$238.8M	$19.9M
Accumulated other comprehensive income	$6.0K	$0
Accumulated deficit	-$160.0M	-$116.6M
Total stockholders' equity (deficit)	$78.8M	-$96.6M	-$45.0M
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	$121.7M	$6.2M
Accrued expenses and other current liabilities	$8.1M	$2.2M
Convertible promissory notes, net of discount		$1.3M
Tranche liability	$0	$365.0K
Redeemable convertible preferred stock, par or stated value per share	$0.00	$0.00
Redeemable convertible preferred stock, shares authorized	0 shares	75.2M shares
Redeemable convertible preferred stock, shares issued	0 shares	43.2M shares
Redeemable convertible preferred stock, shares outstanding	0 shares	43.2M shares
Redeemable convertible preferred stock, liquidation preference	$0	$45.2M
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300.0M shares	86.0M shares
Common stock, shares issued	22.9M shares	1.4M shares
Common stock, shares outstanding	22.9M shares	1.4M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$98.1M	$1.6M
Short-term marketable securities	$19.9M	$0
Prepaid expenses and other current assets	$827.0K	$967.0K
Total current assets	$118.8M	$2.6M
Deferred transaction costs	$0	$3.1M
Operating lease right-of-use assets	$1.5M	$0
Restricted cash	$499.0K	$0
Other non-current assets	$953.0K	$410.0K
Total assets	$121.7M	$6.2M
Accounts payable	$1.3M	$1.6M
Convertible promissory notes, net of discount of $1,298 (including $0 and $18,670 due to a related party)	$0	$19.5M
Derivative liabilities (including $0 and $995 due to a related party)	$0	$1.0M
Operating lease liabilities, current	$316.0K	$0
Total current liabilities	$9.7M	$24.7M
Royalty obligation - related party	$32.1M	$32.1M
Operating lease liabilities, long-term	$1.1M	$0
Total liabilities	$42.9M	$56.8M
Redeemable convertible preferred stock, $0.00001 par value, no shares authorized, issued and outstanding as of December 31, 2025; 75,151,340 shares authorized as of December 31, 2024; 43,151,340 shares issued and outstanding as of December 31, 2024; liquidation preference of $0 as of December 31, 2025	$0	$46.0M
Common stock, $0.0001 and $0.00001 par value as of December 31, 2025 and 2024, respectively; 300,000,000 and 86,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 22,902,418 and 1,356,431 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$2.0K	$0
Additional paid-in capital	$238.8M	$19.9M
Accumulated other comprehensive income	$6.0K	$0
Accumulated deficit	-$160.0M	-$116.6M
Total stockholders' equity (deficit)	$78.8M	-$96.6M	-$45.0M
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	$121.7M	$6.2M
Accrued expenses and other current liabilities	$8.1M	$2.2M
Convertible promissory notes, net of discount		$1.3M
Tranche liability	$0	$365.0K
Redeemable convertible preferred stock, par or stated value per share	$0.00	$0.00
Redeemable convertible preferred stock, shares authorized	0 shares	75.2M shares
Redeemable convertible preferred stock, shares issued	0 shares	43.2M shares
Redeemable convertible preferred stock, shares outstanding	0 shares	43.2M shares
Redeemable convertible preferred stock, liquidation preference	$0	$45.2M
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300.0M shares	86.0M shares
Common stock, shares issued	22.9M shares	1.4M shares
Common stock, shares outstanding	22.9M shares	1.4M shares

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁶

Period ending	2025-12-31	2024-12-31
Net loss	-$43.4M	-$69.2M
Royalty obligation expense - related party		$32.0M
Depreciation expense	$13.0K
Stock-based compensation expense	$1.9M	$895.0K
Capital contributions - in-kind services - related party		$60.0K
Change in fair value of derivative liabilities (including $1,165 and $2,039 for a related party)	-$1.2M	-$2.1M
Non-cash operating lease expense	$53.0K
Net amortization of premiums and accretion of discounts on marketable securities	-$399.0K
Prepaid expense and other current assets	$1.8M	-$803.0K
Other non-current assets	-$355.0K	-$410.0K
Accounts payable	-$88.0K	-$1.0M
Accrued expenses and other current liabilities (including $16 and $0 for a related party)	$2.1M	$115.0K
Operating lease liabilities	-$81.0K
Net cash used in operating activities	-$38.4M	-$20.7M
Purchases of short-term marketable securities	-$34.5M
Maturities of short-term marketable securities	$15.0M
Purchase of property and equipment	-$200.0K
Net cash used in investing activities	-$19.7M
Proceeds from issuance of common stock in private placement	$42.0M
Proceeds from issuance of pre-funded warrants in private placement	$8.0M
Payment of issuance costs	-$1.7M
Proceeds from the issuance of redeemable convertible preferred stock, net of issuance costs		$1.6M
Proceeds from the issuance of convertible promissory notes (including $3,402 and $19,041 from a related party), net of issuance costs	$7.5M	$20.0M
Cash acquired in connection with the Merger	$102.1M
Payment of deferred transaction costs and issuance costs	-$2.9M	-$2.4M
Proceeds from the exercise of stock options		$3.0K
Net cash provided by financing activities	$155.0M	$19.1M
Net increase (decrease) in cash and cash equivalents and restricted cash	$96.9M	-$1.5M
Right-of-use assets obtained in exchange for operating lease liability	$1.5M
Merger transaction costs recognized in additional paid-in capital	$5.4M
Recognition of AlloVir common stock outstanding at the closing of the Merger	$105.0M
Issuance of redeemable convertible preferred stock upon conversion of convertible promissory notes	$3.7M
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger	$49.7M
Conversion of convertible promissory notes and accrued interest in connection with the Merger	$20.8M
Deferred transaction and financing issuance costs included in accounts payable and accrued expenses and other current liabilities	$1.7M	$748.0K
Unrealized gain on available-for-sale securities	$6.0K
Capital contributions in-kind services related party		$60.0K
Premium on issuance of convertible promissory notes (including $169 and $15,296 for a related party)	$186.0K	$16.6M
Repurchase of common stock shares for royalty obligation		$32.0K
Vesting Of Restricted Stock Awards		$1.0K
Change in fair value of tranche liability	$365.0K	$21.0M
Non-cash interest expense	$1.4M	$2.7M
Loss on extinguishment and on issuance of convertible promissory notes	$186.0K	$38.0M

Compare Kalaris Therapeutics, Inc. with another company

Leadership

Who has led Kalaris Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chief financial officer

2025

Chief executive officerDiana Brainard May 18, 2021 to Nov 20, 2024⁸
Chief executive officerDavid Hallal Jul 30, 2020 to Jan 25, 2021⁹
Chief financial officerLiisa Ann Bayko Jul 20, 2026 to now¹⁰
Chief financial officerMatthew Gall Nov 3, 2025 to Jul 20, 2026¹¹

Board members and other officers (26)

OfficerAmy O'Leary Vandekop Jul 27, 2026 to now¹²
OfficerAndrew Oxtoby Mar 18, 2025 to now¹³
Chief Medical OfficerMatthew Feinsod Mar 18, 2025 to now¹⁴
Chief Commercial OfficerCintia Piccina Jun 21, 2023 to Jul 5, 2023¹⁵
OfficerErcem Atillasoy Jul 29, 2020 to Oct 26, 2022¹⁶
Chief Medical OfficerAgustin Melian Jul 30, 2020 to Oct 5, 2021¹⁷
Chief Scientific OfficerAnn M. Leen Jul 30, 2020 to Feb 3, 2023¹⁸
Chief Commercial OfficerBeek Jeroen B. Van Jul 30, 2020 to Nov 18, 2022¹⁹
Chief Accounting OfficerBrett R. Hagen Jul 30, 2020 to now²⁰
OfficerVikas Sinha Jul 30, 2020 to Feb 24, 2025²¹
Board memberAndrew Oxtoby Mar 18, 2025 to now¹³
Board memberAnthony P. Adamis Mar 18, 2025 to now²²
Board memberMichael Dybbs Mar 18, 2025 to now²³
Board memberNapoleone Ferrara Mar 18, 2025 to now²⁴
Board memberSrinivas Akkaraju Mar 18, 2025 to now²⁵
Board memberLeone D. Patterson Apr 4, 2025 to now²⁶
Board memberDerek N. Adams Mar 3, 2023 to Jun 7, 2024²⁷
Board memberShawn Tomasello Mar 31, 2022 to Jun 7, 2024²⁸
Board memberAnsbert Gadicke Jul 29, 2020 to Aug 1, 2022²⁹
Board memberDiana Brainard Jul 29, 2020 to Nov 20, 2024³⁰
Board memberJeffrey S. Bornstein Jul 29, 2020 to Jun 7, 2024³¹
Board memberMalcolm Brenner Jul 29, 2020 to Jun 7, 2024³²
Board memberDavid Hallal Jul 30, 2020 to now⁹
Board memberJuan Vera Jul 30, 2020 to Jun 7, 2024³³
Board memberMorana Jovan-Embiricos Jul 30, 2020 to now³⁴
Board memberVikas Sinha Jul 30, 2020 to Feb 24, 2025²¹

Former names

Allovir, Inc.May 22, 2019 to Mar 12, 2025²
ViraCyte, Inc.Oct 2, 2018 to Oct 2, 2018²

Timeline

May 18, 2021New chief executive Diana Brainard becomes CEO⁸
Jul 30, 2020New chief executive David Hallal becomes CEO⁹

Filings

548 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 55 major events, 266 insider forms, 23 large holders, 183 other. The latest 20:

Aug 28, 20264 EDGAR
Aug 11, 202610-Q EDGAR
Aug 11, 20268-K EDGAR
Aug 3, 20264 EDGAR
Aug 3, 20263 EDGAR
Jul 27, 20263 EDGAR
Jul 20, 20264 EDGAR
Jul 20, 20263 EDGAR
Jul 20, 20268-K EDGAR
Jul 17, 20268-K EDGAR
Jul 6, 20268-K EDGAR
Jun 4, 20264 EDGAR
Jun 4, 20264 EDGAR
Jun 4, 20264 EDGAR
Jun 4, 20264 EDGAR
Jun 4, 20264 EDGAR
Jun 4, 20264 EDGAR
Jun 4, 20264 EDGAR
Jun 4, 20268-K EDGAR
May 22, 2026SCHEDULE 13D/A EDGAR

The 548 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 23 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 57. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Samsara Biocapital, LLC	12,881,175	$52.4M	4.3%	−66,906
Rtw Investments, LP	1,300,000	$5.3M	0.0%	No change
Alyeska Investment Group, L.P.	572,687	$2.3M	0.0%	No change
Siren, L.L.C.	435,798	$1.8M	0.0%	No change
Vanguard Capital Management LLC	398,712	$1.6M	0.0%	+143,364
Ikarian Capital, LLC	360,000	$1.5M	0.2%	No change
UBS Group AG	262,131	$1.1M	0.0%	+255,947
Renaissance Technologies LLC	149,351	$607.9K	0.0%	+83,200
Marshall Wace, Llp	139,201	$566.5K	0.0%	+71,322
Geode Capital Management, LLC	114,037	$464.3K	0.0%	+26,492
Woodline Partners LP	100,000	$407.0K	0.0%	No change
ADAR1 Capital Management, LLC	100,000	$407.0K	0.0%	No change
WHI TRUST Co LLC	97,493	$396.8K	0.3%	No change
Raymond James Financial Inc	97,164	$395.5K	0.0%	−21,723
Citadel Advisors LLC	95,772	$389.8K	0.0%	New
Boothbay Fund Management, LLC	92,261	$375.5K	0.0%	No change
Verdad Advisers, LP	80,297	$326.8K	0.3%	New
Morgan Stanley	72,326	$294.4K	0.0%	+33,982
Vanguard Fiduciary Trust Co	66,179	$269.3K	0.0%	+29,462
BlackRock, Inc.	54,442	$221.6K	0.0%	+18,399
Belpointe Asset Management LLC	40,000	$162.8K	0.0%	No change
Fortis Capital Advisors, LLC	40,000	$162.8K	0.0%	No change
Pale Fire Capital SE	39,626	$161.3K	0.0%	New
Squarepoint Ops LLC	38,775	$157.8K	0.0%	−998
Bridgeway Capital Management, LLC	32,500	$132.3K	0.0%	+10,000

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARKalaris Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARKalaris Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARKalaris Therapeutics, Inc. 10-K for fiscal 2019
4
SEC EDGARKalaris Therapeutics, Inc. 10-Q for fiscal 2026
5
SEC EDGARKalaris Therapeutics, Inc. 10-Q for fiscal 2026
6
SEC EDGARKalaris Therapeutics, Inc. 10-K filed 2026-03-17: income statement
7
SEC EDGARKalaris Therapeutics, Inc. 10-K for fiscal 2019
8
SEC EDGARDiana Brainard, Chief executive officer
9
SEC EDGARDavid Hallal, Chief executive officer
10
SEC EDGARLiisa Ann Bayko, Chief financial officer
11
SEC EDGARMatthew Gall, Chief financial officer
12
SEC EDGARAmy O'Leary Vandekop, Officer
13
SEC EDGARAndrew Oxtoby, Officer
14
SEC EDGARMatthew Feinsod, Chief Medical Officer
15
SEC EDGARCintia Piccina, Chief Commercial Officer
16
SEC EDGARErcem Atillasoy, Officer
17
SEC EDGARAgustin Melian, Chief Medical Officer
18
SEC EDGARAnn M. Leen, Chief Scientific Officer
19
SEC EDGARBeek Jeroen B. Van, Chief Commercial Officer
20
SEC EDGARBrett R. Hagen, Chief Accounting Officer
21
SEC EDGARVikas Sinha, Officer
22
SEC EDGARAnthony P. Adamis, Board member
23
SEC EDGARMichael Dybbs, Board member
24
SEC EDGARNapoleone Ferrara, Board member
25
SEC EDGARSrinivas Akkaraju, Board member
26
SEC EDGARLeone D. Patterson, Board member
27
SEC EDGARDerek N. Adams, Board member
28
SEC EDGARShawn Tomasello, Board member
29
SEC EDGARAnsbert Gadicke, Board member
30
SEC EDGARDiana Brainard, Board member
31
SEC EDGARJeffrey S. Bornstein, Board member
32
SEC EDGARMalcolm Brenner, Board member
33
SEC EDGARJuan Vera, Board member
34
SEC EDGARMorana Jovan-Embiricos, Board member